Get your free Information Pack
Our Brain Tumour Information Pack can help you better understand your diagnosis and feel confident talking to your medical team.
A biomarker is a biological marker or indicator of a certain process happening in the body. If you have a brain tumour, a biomarker test may be used to look at the genes associated with your type of tumour.
With brain tumours, biomarker tests can be used to see if your tumour has certain changes in its genes that may be used to:
Research is still in early stages and it’s important to know that :
Biomarker test results can be useful in giving more detailed information about your tumour type. This can help to give a more accurate diagnosis and plan appropriate, more personalised treatment.
For certain tumour types, they may also suggest how your tumour may respond to certain treatments and also give information that can help estimate your prognosis (likely outcome of your treatment).
The results may also help give an indication as to which clinical trials may be suitable for you. For more information about clinical trials, see our Clinical trials webpage and fact sheet.
While many scientists believe that biomarker testing is helpful, others argue that the results are sometimes unclear due to a number of factors. For example:
Some people prefer not to know too much detail about their tumour and how this might predict their prognosis.
For example, if you have a biomarker test which suggests your tumour type doesn’t respond well to treatment, this is likely to be difficult news. If you’ve been working hard to maintain a positive frame of mind on a day-to-day basis, this could set you back.
Quite often biomarker testing is done routinely, so you may not be consulted before this is done. You can, of course, choose not to be told the result.
Ask your healthcare team if testing is done routinely and, if it’s not, think about it carefully and discuss it with them and your family before deciding whether to ask for it.
Many tumours are heterogeneous. This means all the cells are not the same. Instead, some cells, or groups of cells, throughout the tumour will have different genetic mutations (changes in the genes) or a different molecular make-up.
If a sample is taken from a part of a tumour that’s different to the rest of the tumour, it may show different results to a sample taken from elsewhere in the same tumour.
This means that the results of the biomarker test may not truly reflect the tumour and its likely behaviour.
For more information about biopsies, see our Neurosurgery for brain tumours webpage and fact sheet.
The 1p/19q test may predict long-term survival in people who have some types of brain tumour.
The test can also be useful in diagnosing certain types of brain tumours and, therefore, in making decisions about the most appropriate treatment for you.
The types of brain tumour that may be suitable for 1p/19q testing are:
Our bodies are made up of cells. Each cell has 23 pairs of chromosomes, which carry your genes (DNA). One chromosome of each pair is inherited from your mother, and the other from your father. Each pair of chromosomes are numbered 1 to 22, then XX or XY.
The 1p/19q test looks at genetic changes to chromosomes 1 and 19 to see whether they have a section missing. If the sections called the p section of chromosome 1 and the q section of chromosome 19 are missing, this means that the genes carried in those sections are also missing.
These genes seem to be involved in resistance to chemotherapy drugs. So if you’re found to be missing both those sections, you’re more likely to have a better response to chemotherapy and longer overall survival.
The histone H3.K3 27M test may predict response to treatment for certain types of tumour.
The histone H3.3 K 27M test is suitable for:
· Paediatric diffuse midline gliomas (previously called DIPG )
Up to 80% of paediatric diffuse midline gliomas have a mutation of the histone H3. A histone is a group of proteins that your DNA wraps round in your chromosomes.
The IDH1/IDH2 test may predict long-term survival in people who have certain types of brain tumour. It may also be useful in predicting how effective a particular treatment is likely to be.
If you have a glioma, you may be suitable for IDH1/IDH2 testing, but speak to your neuro-oncologist for information and advice.
Gliomas that may be suitable include:
· Diffuse astocytomas (grade 2)
· Anaplastic astrocytomas (grade 3)
· Glioblastomas, in particular secondary glioblastomas (tumours that evolved from lower grade gliomas )
IDH1 and IDH2 are genes. A change (mutation) in the IDH1/IDH2 genes has been found in about 80% of astrocytomas, oligodendrogliomas and secondary glioblastomas.
Tumours that have the change are known as IDH–mutant, and those without the change are known as IDH-wildtype.
For people with high grade types of these glioma, those whose tumours are IDH-mutant tend to have better long-term survival rates than those who are IDH-wildtype.
It’s not yet clear how mutations of the IDH1/IDH2 genes link to outcomes for people with low grade brain tumours - both in terms of long-term survival and also treatment outcomes. However, there’s some evidence that, similar to high grade gliomas, people whose tumours are IDH-mutant have better long-term survival rates than those who are IDH-wildtype.
Further research needs to be carried out before clear conclusions can be drawn, but it may be that chemoradiotherapy (a combination of chemotherapy and radiotherapy) is more effective for some people with grade 2 gliomas who have the IDH1/IDH2 mutation, than those who don’t. (See TP53/ATRX mutations section further on.)
It’s important to be aware that people with gliomas that have the IDH1/IDH2 mutation tend to be younger adults and older children, which may partially account for their longer survival.
For people with certain tumour types, the MGMT methylation test helps to predict how effective chemotherapy treatment is likely to be, although there are many other factors that also affect response to treatment. This can be used to help plan a suitable, individualised treatment plan.
NICE (National Institute for Health and Care Excellence) recommends that all high grade glioma tumours should be tested for MGMT promoter methylation to inform prognosis and guide treatment.
The types of brain tumour suitable for MGMT biomarker testing include:
You may have heard of recent research that suggested that the MGMT test may also be useful for predicting prognosis in grade 2 gliomas. This research is in very early stages and is not evidence-based. More research is needed to confirm if this is the case.
In summary, the test looks at the amount (percentage) of something called methylation. If your tumour is found to be:
This helps your healthcare team decide on the best course of treatment for you. For example, if your tumour is unmethlyated, giving you high doses of chemotherapy may give you lots of unpleasant side-effects, but with little benefit in terms of reducing your tumour.
If you do decide to have the test, you need to be aware that it may be found to be unmethylated. Speak to your healthcare team about what would happen next if this turned out to be the case.
There are other factors that influence the effectiveness of chemotherapy, so there’ll always be ‘good’ and ‘poor’ responders in both the methylated and unmethylated groups.
If you’d like to understand the test more:
There’s some debate about what percentage marks a tumour as methylated and what as unmethylated. As a result, the test isn’t 100% accurate.
When found with 1p/19q co-deletion and IDH-mutant biomarkers, the TERT promoter mutation suggests a diagnosis of oligodendroglioma, and predicts greater benefit from chemotherapy and radiotherapy and longer survival, particularly in grade 2 and 3 gliomas.
However, when the TERT mutation is found on its own in grade 2 and 3 gliomas, it predicts poorer survival. This suggests the need for early, more aggressive treatment.
When the TERT mutation is found with IDH-wildtype, this suggests a diagnosis of glioblastoma. In higher grade gliomas, such as glioblastoma, the TERT mutation is associated with poor overall survival.
It’s thought that the TERT mutation may also worsen the poor response to treatment (temozolomide and radiotherapy) in MGMT unmethylated glioblastomas.
Frequently found in adult diffuse gliomas (grades 2 and 3) and often in astroctyomas with IDH1/2 mutations, these biomarkers are useful in confirming the diagnosis of these tumours.
Tumours that are IDH-mutated and have mutations in ATRX and TP53 grow more slowly than tumours without the IDH-mutation, but have also been found to be resistant to radiotherapy.
This means radiotherapy is less likely to kill these tumour cells, and so is less effective in tumours with these mutations.
However, in low grade gliomas, if the radiotherapy is combined with chemotherapy drugs that block the repair of DNA, this can result in longer survival than receiving radiotherapy alone.
TP53 has also been found to help predict prognosis in the sub-type of medulloblastomas known as SHH (sonic hedgehog) type. SHH types of medulloblastoma with a mutation in TP53 tend to have a worse prognosis.
There are 2 different mutations in the BRAF gene that may be of interest. These are the KIAA1549-BRAF fusion gene in childhood brain tumours and the BRAF V600E mutation in adult brain tumours.
The BRAF test (along with other investigations) can sometimes help determine whether a tumour is a pilocytic astrocytoma (a type of grade 1 tumour) rather than another type of (non-pilocytic) astrocytoma, if there’s uncertainty. These tumours are more common in children than adults.
There is some evidence that a mutation in the KIAA1549-BRAF fusion gene can cause poorer outcomes in low grade gliomas in children.
The BRAF V600E mutation in adults may increase the growth and spread of tumour cells. This is being investigated as a target for various drugs.
BRAF testing is only clinically useful in a few selected tumour types and is most commonly used to determine whether a tumour is a pilocytic astrocytoma.
If you’re interested in BRAF testing, please speak to your neuro-oncologist for information and advice.
BRAF is a gene that makes a protein called B-raf. The B-raf protein is important because it sends signals to direct the growth of cells within our body. This is known as the MAPK pathway inside the cell.
Research has found that some brain tumours (types of grade 1 and 2 astrocytoma, including grade 1 pilocytic astrocytoma) may have a fault with their BRAF gene.
The fault leads to the BRAF gene permanently sending signals that make cells divide and create copies of themselves. This uncontrolled growth of cells contributes to tumour formation.
Research into the molecular structure of brain tumour cells is ongoing and is leading to increased understanding of the role genes play in a tumour’s behaviour. As a result, other possible biomarkers are of interest.
Many of these other genes and mutations have shown some association with survival and tumour behaviour, but many of these tests are very experimental and remain under investigation. As a result, they’re not yet routinely offered as their value in clinical practice has yet to be determined.
Many other genes and mutations have been associated with survival and tumour behaviour. However, many of these remain under investigation and aren’t yet routinely used.
A mutation in the EGFRvlll gene is found in about 20-30% of glioblastomas, and is tumour-specific. This means it’s not found in normal brain tissue.
As a result, its presence can confirm a diagnosis of glioblastoma. Although it’s important to note that its absence doesn’t mean it’s not a glioblastoma.
As it only appears in tumour cells, it could also be used as a target for treatments, as well as predicting prognosis. Research is underway and this test isn’t routinely offered.
Recent research has identified markers, which can predict prognosis, in particular sub-types of childhood medulloblastomas - the sub-types known as SHH (with TP53 wildtype), Group 3 and Group 4.
A pattern of chromosome gains and losses was found that could separate these sub-types, normally classified as standard-risk, into favourable-risk and high-risk categories.
Those in the favourable-risk group would need less intensive, aggressive chemotherapy, and so have fewer side-effects.
Sometimes when a cell is dividing, a mistake can be made and 2 separate genes can fuse together. These fusion genes can make fusion proteins.
It’s been found that children with certain types of brain tumour and fusions of the YAP1 protein had better prognoses than children without the fusion, known as YAP1-wildtype. These include childhood supratentorial subependymomas and ependymomas.
The number of centres offering biomarker testing is growing as research in the area develops. In some centres, biomarker testing is now done routinely (when your neuro-oncologist thinks a particular test would be appropriate to your tumour type) and in line with NICE recommendations.
NICE recommends the following tests should be carried out for all gliomas:
NICE also recommends:
As many of these NICE recommended biomarkers are also now part of the latest WHO classification system of brain tumours, they should be offered by all neuro-oncology centres. (WHO= World Health Organisation.)
You may have had it done without realising. Speak to your healthcare team if you want to know if this is the case.
If it hasn’t been done routinely and you’re interested in having a biomarker test, the first thing you’ll need to do is speak to your neuro-oncologist. They’ll be able to tell you whether they think it’s suitable for you. You can ask this question at any time.
If they feel it would be beneficial, they may arrange for the test to happen at the hospital you’re being treated at. If the hospital doesn’t carry out such tests, they may refer you elsewhere.
It’s important to note that the tests won’t necessarily influence your treatment plan at the hospital you attend. So, as the hospital has to pay for the test, unless the neuro-oncologist is going to change your treatment on the basis of the test result, they may not feel that testing is necessary.
If your neuro-oncologist doesn‘t believe that biomarker testing would be beneficial to you, you can ask them to talk through with you how they’ve made their decision.
If, after this, you’d still like to pursue biomarker testing, you may wish to ask your medical insurers, if you have private medical insurance, if they would pay for them.
Or you may wish to have the testing done privately and pay for it yourself. Either way, you’ll need to provide information, and possibly biopsy samples. To obtain these, speak to your neuro-oncologist.
It’s important to be aware that any biomarkers outside the NICE recommended group are unlikely to be funded outside of a research study (clinical trial).
For more information about biomarkers, download our free factsheet.
You may have heard your neuro-oncologist use some of the terms mentioned in this fact sheet when referring to your specific tumour type. If you’re finding this overwhelming or difficult to understand, you’re not alone. Speak to your healthcare team if you have questions, or please contact our Information and Support Team.
If you have further questions, need to clarify any of the information on this page, or want to find out more about research and clinical trials, please contact our team:
0808 800 0004 (free from landlines and mobiles)
Phone lines open Mon-Fri, 09:00-17:00
You can also join our active online community on Facebook - find out more about our groups.